PDCD1 and neoplasm: As an example, following neoadjuvant anti-PD-1 and gemcitabine, adjuvant therapy with anti-CD96 resulted in a significant survival benefit in pancreatic ductal adenocarcinoma (PDAC) tumor-bearing mice (153).